NEJM: A study of the efficacy of oxytosinib as an auxiliary treatment after surgery for non-small cell lung cancer

Osimertinib is a standard nursing therapy for advanced non-small cell lung cancer (NSCLC), which was previously positive for the previously untreated skin growth factor (EGFR) mutation, and has excellent therapeutic effect on NSCLC patients with EGFR T790M mutation.
recently examined the effectiveness and safety of oxytini as an auxiliary treatment after surgery.
In this double-blind Phase III trial, patients with EGFR mutation-positive NSCLC received oxytinib (once a day, 80 mg) or a placebo for 3 years after a complete removal surgery.
end of the study was the disease-free survival rate of patients from stage II to IIIA, and the secondary endpoint included disease-free survival, total survival and safety in patients from IB to IIIA.
682 patients were involved in the study, 339 of whom were treated with oxytinib and 343 who received a placebo.
At 24 months, 90 percent of patients in the Ositeni group had stage II to IIIA, and 44 percent of patients in the placebo group in stage II to IIIA achieved disease-free survival (the total risk ratio of recurrence or death was 0.17).
In the general population, 89 percent of patients in the Ossiny group and 52 percent of patients in the placebo group achieved disease-free survival at 24 months (the overall risk of disease recurrence or death was 0.20).
24 months, 98 percent of patients in the Ositeni group and 85 percent in the placebo group survived without central nervous system disease (the overall risk of recurrence or death was 0.18).
total of 29 patients died, including 9 in the Ositeni group and 20 in the placebo group.
found no new security issues.
study concluded that for patients with non-small cell lung cancer who were positive for EGFR mutations in the period from IB to IIIA, receiving Ositeni treatment after surgery significantly prolonged the patient's disease-free survival.